A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043
Recruiting
ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: AnaptysBio Investigational Site 10-115, Phoenix, Arizona +99 locations
Conditions: Ulcerative Colitis
Register for Updates
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
NCT06161519
Recruiting
Background: About 90,000 new cases of brain and spinal cord tumors are diagnosed annually in the United States. Most of these tumors are benign; however, about 30% are malignant, and 35% of people with malignant tumors in the brain and spinal cord will die within 5 years. Many of these people have changes in certain genes (MYC or MYCN) that drive the development of their cancers. Objective: To test a study drug (PLX038) in people with tumors of the brain or spinal cord. Eligibility: People... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Glioma, Medulloblastoma, Ependymoma
Register for Updates
Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes
NCT00001405
Recruiting
The research goal of this study is to obtain CD34+ hematopoietic stem cells (HSC) from peripheral blood and/or bone marrow, and Mononuclear Cells (lymphocytes and monocytes), and granulocytes (grans) from peripheral blood that will be used in the laboratory and/or in the clinic to develop new cell therapies for patients with inherited or acquired disorders of immunity or blood cells. Development of novel cellular therapies requires access to HSC, Mononuclear Cells and/or granulocytes as the esse... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Granuloma, Granulomatous Disease, Chronic, Leukocyte Disease, Genetic Disease, X-Linked, Genetic Disease, Inborn
Register for Updates
University of Minnesota Transplant Registry
NCT01062581
Recruiting
Under Transplant Information Services (TIS), the University of Minnesota Transplant Registry (UMTR) will serve as the repository for core research data.
Gender:
ALL
Ages:
All
Trial Updated:
03/21/2025
Locations: University of Minnesota Transplant Information Services, Minneapolis, Minnesota
Conditions: Transplant Recipient, Transplant Donation
Register for Updates
Epidural Stimulation After Neurologic Damage
NCT03026816
Recruiting
This study will evaluate a method to optimize parameter settings in epidural spinal cord stimulation used to recover lower extremity volitional movement. The study will also characterize improvement in autonomic function (such as blood pressure control) and other functions related to spinal cord injury.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/21/2025
Locations: Hennepin County Medical Center, Minneapolis, Minnesota
Conditions: Spinal Cord Injuries, Paraplegia, Complete
Register for Updates
High Resolution Micro OCT Imaging
NCT03256773
Recruiting
The purpose of this study is to learn about using the imaging to make images of the lungs and nose with the long-term goal of the research leading to potential treatments and new therapies for patients with cystic fibrosis.
Gender:
ALL
Ages:
14 years and above
Trial Updated:
03/21/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis
Register for Updates
The Venous Distension Reflex and Orthostatic Hypertension
NCT03496792
Recruiting
This research is being done to find out whether distension of veins in legs will cause a rise in blood pressure (orthostatic hypertension).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Blood Pressure
Register for Updates
Autonomic Control of the Circulation and VDR
NCT03513770
Recruiting
The study objective of this project is to examine the mechanisms of the venous distension reflex (VDR) in humans. We hypothesize that COX blockade with ketorolac tromethamine, an intravenous NSAID, will attenuate the muscle sympathetic nerve activity (MSNA) response to limb venous distension. To gain further insight into whether the COX byproducts directly stimulate chemically-sensitive afferents, or enable venodilation and indirectly evoke afferent stimulation, we will measure vein size using 3... Read More
Gender:
ALL
Ages:
Between 21 years and 35 years
Trial Updated:
03/21/2025
Locations: Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Venous Distension Reflex, Blood Pressure
Register for Updates
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
NCT04157985
Recruiting
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. The investigators anticipate that the results of this study will answer questions regarding the optimal duration of treatment. therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
Register for Updates
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
NCT04486833
Recruiting
The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer. The study is comprised of a Phase 1 dose escalation portion and two Pha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Valkyrie Clinical Trials, Los Angeles, California +7 locations
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763
Recruiting
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +37 locations
Conditions: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Register for Updates
Early Intervention for Youth At High Risk for Bipolar Disorder
NCT04815239
Recruiting
Investigators will conduct a confirmatory efficacy trial of Interpersonal and Social Rhythm Therapy (IPSRT) delivered via telehealth for offspring of bipolar parents (OBP; age 12-18, n=120) at elevated risk for BP onset via risk calculator score. All participants receive a baseline clinical assessment of psychiatric symptoms and sleep disturbance (via objective and subjective methods), followed by a feedback session. Youth are then randomized to receive 8 sessions of IPSRT or a manualized Health... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
03/21/2025
Locations: Nicole Arnold, Pittsburgh, Pennsylvania
Conditions: Bipolar Disorder
Register for Updates